Inclusion Criteria:

- Signed and dated, institutional review board (IRB) or independent ethics committee
(IEC)-approved informed consent form before any protocol-specific screening
procedures

- Histologic and/or cytologic diagnosis of locally-advanced or metastatic non-small
cell lung cancer in subjects who are not curable by conventional therapy

Exclusion Criteria:

- Chemotherapy, radiotherapy, anticancer immunotherapy, or investigational agents
within 4 weeks of treatment day 1 (6 weeks if the previous regimen included
mitomycin or nitrosoureas)

- Prior radiotherapy to >25% of bone marrow

- Prior epidermal growth factor receptor-targeting therapy